Table 1.

Drug-gene dose relationship results. Drug-gene pairs are presented in three groups: drugs with CPIC guidelines, without guidelines but PharmGKB evidence, and novel associations. Level of Evidence represents the maximum level of evidence for the drug-gene relationship in PharmGKB.

Group	Drug	Gene	Level of Evidence	# Samples	Test	p-value
CPIC guidance	warfarin	CYP2C9	1A	6,409	JT	0.00E+00
	phenytoin	CYP2C9	1A	459	KW	1.04E-05
	azathioprine	TPMT	1A	799	KW	9.13E-03
	imipramine	CYP2C19	2A	348	JT	1.10E-23
	lansoprazole	CYP2C19	2A	2,793	JT	2.52E-02
	pantoprazole	CYP2C19	3	114	JT	2.56E-02
	simvastatin	SLCO1B1	1A	34,611	KW	3.52E-02
	warfarin	CYP4F2	1A	4,559	KW	3.69E-02
	paroxetine	CYP2D6	1A	2,804	KW	4.22E-02
No guidance	warfarin	CYP2C19	3	6,410	KW	2.22E-14
	nicotine	CYP2B6	3	391	JT	6.38E-04
Novel associations	cyclosporine	CYP2C19	NA	166	JT	1.87E-05*
	rabeprazole	CYP2C9	NA	223	JT	4.55E-05*

p-values with a * are significant at p <= 8.6 x 10⁻⁶, bonfenoni adjusted.

Test indicates which type of test achieved the p-value shown (JT=Jonckheere-Terpstra, KW=Kraskal Wallis). Only results with a standard enor less than 0.2 are included.